119 related articles for article (PubMed ID: 38604764)
21. Preclinical evaluation of a dual-receptor targeted tracer [
Lv X; Song X; Long Y; Zeng D; Lan X; Gai Y
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):54-67. PubMed ID: 37642706
[TBL] [Abstract][Full Text] [Related]
22. In Vivo Evaluation and Dosimetry Estimate for a High Affinity Affibody PET Tracer Targeting PD-L1.
Rubins DJ; Meng X; McQuade P; Klimas M; Getty K; Lin SA; Connolly BM; O'Malley SS; Haley H; Purcell M; Gantert L; Holahan M; Lindgren J; Eklund P; Ekblad C; Frejd FY; Hostetler ED; González Trotter DE; Evelhoch JL
Mol Imaging Biol; 2021 Apr; 23(2):241-249. PubMed ID: 33098025
[TBL] [Abstract][Full Text] [Related]
23. High in-vivo stability in preclinical and first-in-human experiments with [
Qin X; Guo X; Liu T; Li L; Zhou N; Ma X; Meng X; Liu J; Zhu H; Jia B; Yang Z
Eur J Nucl Med Mol Imaging; 2023 Jan; 50(2):302-313. PubMed ID: 36129493
[TBL] [Abstract][Full Text] [Related]
24. Development, preclinical evaluation and preliminary dosimetry profiling of SB03178, a first-of-its-kind benzo[h]quinoline-based fibroblast activation protein-α-targeted radiotheranostic for cancer imaging and therapy.
Bendre S; Merkens H; Kuo HT; Ng P; Wong AAWL; Lau WS; Zhang Z; Kurkowska S; Chen CC; Uribe C; Bénard F; Lin KS
Eur J Med Chem; 2024 Mar; 268():116238. PubMed ID: 38367492
[TBL] [Abstract][Full Text] [Related]
25. Biodistribution, pharmacokinetics, dosimetry of [
Ballal S; Yadav MP; Moon ES; Kramer VS; Roesch F; Kumari S; Tripathi M; ArunRaj ST; Sarswat S; Bal C
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):1915-1931. PubMed ID: 33244617
[TBL] [Abstract][Full Text] [Related]
26. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT.
Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238
[TBL] [Abstract][Full Text] [Related]
27. ImmunoPET imaging of human CD8
Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
[TBL] [Abstract][Full Text] [Related]
28. [
Hu K; Wang L; Wu H; Huang S; Tian Y; Wang Q; Xiao C; Han Y; Tang G
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2833-2843. PubMed ID: 34893920
[TBL] [Abstract][Full Text] [Related]
29. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients.
Zhou X; Jiang J; Yang X; Liu T; Ding J; Nimmagadda S; Pomper MG; Zhu H; Zhao J; Yang Z; Li N
J Nucl Med; 2022 Apr; 63(4):536-542. PubMed ID: 34326125
[No Abstract] [Full Text] [Related]
30. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
31. Whole-Body Integrated [
Guberina N; Hetkamp P; Ruebben H; Fendler W; Grueneisen J; Suntharalingam S; Kirchner J; Puellen L; Harke N; Radtke JP; Umutlu L; Hadaschik BA; Herrmann K; Forsting M; Wetter A
Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413
[TBL] [Abstract][Full Text] [Related]
32. Translational Development of a Zr-89-Labeled Inhibitor of Prostate-specific Membrane Antigen for PET Imaging in Prostate Cancer.
Vázquez SM; Endepols H; Fischer T; Tawadros SG; Hohberg M; Zimmermanns B; Dietlein F; Neumaier B; Drzezga A; Dietlein M; Schomäcker K
Mol Imaging Biol; 2022 Feb; 24(1):115-125. PubMed ID: 34370181
[TBL] [Abstract][Full Text] [Related]
33. Pilot study of a novel nanobody
Wang Y; Wang C; Huang M; Qin S; Zhao J; Sang S; Zheng M; Bian Y; Huang C; Zhang H; Guo L; Jiang J; Xu C; Dai N; Zheng Y; Han J; Yang M; Xu T; Miao L
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4394-4405. PubMed ID: 35829748
[TBL] [Abstract][Full Text] [Related]
34. Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.
Chatalic KL; Franssen GM; van Weerden WM; McBride WJ; Laverman P; de Blois E; Hajjaj B; Brunel L; Goldenberg DM; Fehrentz JA; Martinez J; Boerman OC; de Jong M
J Nucl Med; 2014 Dec; 55(12):2050-6. PubMed ID: 25413139
[TBL] [Abstract][Full Text] [Related]
35. [
Banihashemian SS; Divband G; Pirayesh E; Nikkholgh B; Amini H; Shahrnoy AA; Nami R; Akbari ME
Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):1981-1988. PubMed ID: 38376804
[TBL] [Abstract][Full Text] [Related]
36. Gallium-68-Labeled Z
Li X; Li Z; Huang M; Wang R; Li M; Yang H; Lu X; Cai H; Tian R
Mol Pharm; 2023 Feb; 20(2):1357-1364. PubMed ID: 36692381
[TBL] [Abstract][Full Text] [Related]
37.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
38. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
39.
Kline B; Yadav S; Seo Y; Ippisch RC; Castillo J; Aggarwal RR; Kelley RK; Behr SC; Flavell RR; Lawhn-Heath C; Melisko M; Rugo HS; Wang V; Yom SS; Ha P; Jiang F; Hope TA
J Nucl Med; 2024 Jun; 65(6):938-943. PubMed ID: 38697672
[TBL] [Abstract][Full Text] [Related]
40. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
Backhaus P; Gierse F; Burg MC; Büther F; Asmus I; Dorten P; Cufe J; Roll W; Neri D; Cazzamalli S; Millul J; Mock J; Galbiati A; Zana A; Schäfers KP; Hermann S; Weckesser M; Tio J; Wagner S; Breyholz HJ; Schäfers M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1822-1832. PubMed ID: 34957527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
